Priaxon announces a collaboration with GlaxoSmithKline (GSK) to establish and develop novel drug discovery approaches to address protein-protein-interactions with small molecules
Munich, Germany, January 8, 2013 / B3C newswire / - Priaxon, an emerging pharmaceutical company based in Germany, today announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modulation of protein-protein interactions (PPIs). PPIs play an important role in many cell signaling pathways and cell-surface receptor-ligand interactions that become dysregulated in disease states.
This collaboration will work to identify and advance candidates from hits to leads for pre-clinical development, with the long term interest of developing and commercialising drug candidates. The agreement has been signed following a successful pilot project. Financial details as well as therapeutic fields of the collaboration are not disclosed.
"Using the strength of its unique drug discovery platform Priaxplore®, Priaxon will develop new small molecule modulators for hard-to-drug PPI targets," said Dr. Juergen Kolb, CEO of Priaxon. "Our collaboration with GSK and its experts provides the resources and the capabilities to drive these programs forward. We are looking forward to working together with the goal to develop small molecule modulators for various protein-protein interaction of high potential."
Protein-protein-interactions (PPIs) are highly attractive targets for a variety of indications and could become successors of kinases as prime targets for a whole era. PPIs pertain to numerous therapeutic fields like cardiovascular and metabolic diseases or oncology. This class of targets has been regarded as undrugable for a long time. Now, successful approaches to address this class together with their high relevance in cellular signaling pathways and regulation make them attractive potential targets for future developments. Chemistry and technology of Priaxon are particularly suited for addressing PPIs.
Priaxon is an emerging pharmaceutical company building a pipeline of novel drug candidates in different therapeutic fields, but mainly focusing on protein-protein interactions in oncology and other diseases. Priaxon uses its unique and proprietary drug discovery technology platform Priaxplore® which employs novel methods of chemical synthesis and computational design to discover and develop new chemical entities as candidates for validated but hard-to-drug targets.
Dr Jürgen Kolb, CEO
Gmunder Str. 37-37a
Phone: +49 - 89 - 4521308-20